OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 20th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. Jain on Response and Resistance to Venetoclax in Relapsed/Refractory MCL

May 20th 2020

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

May 20th 2020

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC

May 20th 2020

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Dr. Hidalgo Medina on Promising Research in Pancreatic Cancer

May 20th 2020

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 20th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Dr. Klein on the Importance of the Importance of Prognostic Genomic Assays in Prostate Cancer

May 20th 2020

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Agarwal on the FDA Approval of Olaparib in HRR-Mutant mCRPC

May 19th 2020

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

May 19th 2020

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Dr. Hormigo on the Impact of COVID-19 on High Density Areas

May 19th 2020

Adilia Hormigo, MD, PhD, discusses the impact of the coronavirus disease 2019 (COVID-19) on high density areas.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 19th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Raez on Safety Measures to Combat Challenges of COVID-19 in Lung Cancer

May 19th 2020

Luis E. Raez, MD, discusses the safety measures that have been put in place at Memorial Cancer Institute in response to the coronavirus disease 2019 (COVID-19) in lung cancer.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 19th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. Schroeder on the Importance of JAK Inhibition in GVHD

May 19th 2020

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

May 19th 2020

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

May 19th 2020

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Carbone on the Impact of Immunotherapy in Lung Cancer

May 19th 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Dr. Rugo on Recent Updates With Immunotherapy in TNBC

May 19th 2020

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Dr. Savvides on the Utility of Immunotherapy in Lung Cancer

May 19th 2020

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.